NKP-1339, a first-in-class anticancer drug showing mild side effects and activity in patients suffering from advanced refractory cancer

Benzer Materyaller

• Molecular mode of action of NKP-1339 – a clinically investigated ruthenium-based drug – involves ER- and ROS-related effects in colon carcinoma cell lines
  Yazar:: Flocke, Lea S., ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo()
  Yazar:: Heffeter, Petra, ve diğerleri
  Baskı/Yayın Bilgisi: (2013)
• Electronic State of Sodium trans-[Tetrachloridobis(1H-indazole)ruthenate(III)] (NKP-1339) in Tumor, Liver and Kidney Tissue of a SW480-bearing Mouse
  Yazar:: Blazevic, Amir, ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Intracellular protein binding patterns of the anticancer ruthenium drugs KP1019 and KP1339
  Yazar:: Heffeter, Petra, ve diğerleri
  Baskı/Yayın Bilgisi: (2010)
• Mechanisms underlying reductant-induced reactive oxygen species formation by anticancer copper(II) compounds
  Yazar:: Kowol, Christian R., ve diğerleri
  Baskı/Yayın Bilgisi: (2011)